Pemetrexed Disodium (Pemetrexed Disodium) Patent Expiration, LOE Window & CMS Spending

Pemetrexed Disodium (Pemetrexed Disodium) by Sandoz: Off-Patent Genericized (AB Competition), 17 AB generics, $9.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSandoz
FDA Application & PathwayN214657 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors17
2024 CMS Total Public Spend$9.8M
2024 Medicare Part D Spend$2.4M
2024 Medicaid Spend$7.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel